Dopamine neuron platform for screening molecular mechanisms and inhibitory drugs against alpha-synuclein aggregation
Objective: Optimization of a dopamine neuron based,in vitro platform is beneficial for studying molecular mechanisms of alpha-synuclein aggregation,and screening of inhibitory drugs and deducing their…Development and validation of clinical scales for defining RBD severity in participants of the North American Prodromal Synucleinopathy (NAPS) consortium
Objective: The objective of this study is to assess the internal validity of the REM Sleep Behavior Disorder (RBD) symptom severity scale (RBDSSS) and its…A clinico-genetic study based on the Innsbruck MSA Registry
Objective: To assess family history (FH) for neurodegenerative disorders in people with multiple system atrophy (MSA), compare its prevalence with that of a prospectively recruited…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Central olfactory structure atrophy is linked to synucleinopathy conversion in idiopathic REM sleep behavior disorder
Objective: We hypothesized that early structural changes in the brain olfactory relevant structures may help early identification of those at risk of future disease conversion…Addressing pathological alpha-synuclein aggregation using a small molecule strategy
Objective: The discovery of cell-permeable, orally bioavailable and brain penetrant small molecules with the potential of inhibiting aggregation and intracellular accumulation of pathological alpha-synuclein (a-syn)…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…Remote keyboard tapping: potential signatures of early motor dysfunction in isolated REM sleep behaviour disorder
Objective: To compare keyboard tapping performance in people with iRBD with controls. Background: The Distal Finger Tapping (DFT)1 test and BRadykineisa Akinesia Incoordination test (BRAIN)2…Differential proteomic analysis of plasma exosomes in Parkinson disease associated with mutations in the GBA gene
Objective: To identify the protein changes and to search the potential biomarkers of PD among GBA mutation carriers. Background: Mutations in the GBA gene encoding glucocerebrosidase enzyme are the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »